


Breakthrough in Pretreated *EGFR*-Mutated NSCLC

Final Overall Survival (OS) Analysis of the Phase 2 OptiTROP-Lung03 Study

Overall Survival (OS) Advantage

Median OS for Sac-TMT 20 Mos

Docetaxel 13.5 Mos



18-Month Milestone
54.7% OS rate for Sac-TMT
vs 34.0% for Docetaxel

Progression-Free Survival (PFS)

Median PFS for Sac-TMT 7.9 Mos

Docetaxel 2.8 Mos



12-Month Milestone
30.2% PFS rate for Sac-TMT
vs 2.2% for Docetaxel

Note: After adjusting for crossover, median OS remained 20.0 months in the sac-TMT arm vs 11.2 months in the docetaxel arm.

Safety & Tolerability

0% treatment-related deaths or discontinuations for Sac-TMT

Serious adverse effects were nearly halved in the Sac-TMT group (20.9%) compared with docetaxel (41.3%).



Treatment Duration

Patients stayed on Sac-TMT much longer (Median 7.1 months vs 2.8 months).



Common Adverse Effects (Sac-TMT)

Anemia (81.3%)
Decreased WBC (74.7%)
Decreased neutrophils (68.1%)
Stomatitis (65.9%)

Key Takeaway

“Sac-TMT is the first therapy to achieve long-term OS benefits in patients with advanced *EGFR*-mutated NSCLC who progressed after *EGFR* TKI and platinum-based chemotherapy.”

Follow-up: 23.8 months.